Ruxolitinib

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 249-257

  Becker, Heiko ^a   Engelhardt, Monika ^a   von Bubnoff, Nikolas ^a   Wäsch, Ralph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; ERYTHROMYCIN; ERYTHROPOIETIN; GLUCOCORTICOID; HYDROXYUREA; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; KETOCONAZOLE; LEPTIN; PLACEBO; RIFAMPICIN; RUXOLITINIB; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ANEMIA; ARTICLE; CANCER SURVIVAL; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HEADACHE; HUMAN; IC50; LEUKOCYTE COUNT; MYELOFIBROSIS; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SKIN BRUISING; SPLEEN SIZE; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANIMAL; DRUG ANTAGONISM; MYELOID METAPLASIA; REVIEW;

ANIMALS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES;

EID: 84905818825     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_16     Document Type: Article

References (21)

1. Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13): 2895-2901.
2. Harrison C, Kiladjian JJ, Al-Ali HK et al (2012a) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9): 787-798.
3. Harrison CN, Gisslinger H, Miller CB et al (2012b) Expand: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 9 109/L and 99 9 109/L. Blood 120 (abstract 177) (ASH Annual Meeting Abstracts).
4. James C, Ugo V, Le Couédic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037): 1144-1148.
5. Mascarenhas J, Hoffman R (2013) A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood 121(24): 4832-4837.
6. Mertens C, Darnell JE Jr (2007) SnapShot: JAK-STAT signaling. Cell 131(3): 612.
7. Mesa RA, Yasothan U, Kirkpatrick P (2012) Ruxolitinib. Nat Rev Drug Discov 11(2): 103-104.
8. Mesa RA, Gotlib J, Gupta V et al (2013) Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 31(10): 1285-1292.
9. Quintás-Cardama A, Vaddi K, Liu P et al (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15): 3109-3117.
10. Shi JG, Chen X, Emm T et al (2012) The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 52(6): 809-818.
11. Shilling AD, Nedza FM, Emm T et al (2010) Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos 38(11): 2023-2031.
12. Talpaz M, Hamburg SI, Jamieson K et al (2012a) Preliminary safety and efficacy from a phase II stud of ruxolitinib in patients with primary and secondary myelofibrosis with platelet counts of 50-100 9 109/L. Haematologica 97(s1): 245 (abstract 0597).
13. Talpaz M, Paquette R, Afrin L et al (2012b) Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 9 109/L): a comparison to patients with normal or high starting platelet counts. Blood 120 (abstract 176) (ASH Annual Meeting Abstracts).
14. Tefferi A, Pardanani A (2011) Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 86(12): 1188-1191.
15. Tefferi A, Litzow MR, Pardanani A (2011) Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365(15): 1455-1457.
16. Vannucchi A, Cervantes F, Niederwieser D et al (2013) Long-term outcomes from a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF): a 3-year update of COMFORT-II. Haematologica 98(s1): 456 (abstract S1111).
17. Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12): 1117-1127.
18. Verstovsek S, Kantarjian HM, Estrov Z et al (2012a) Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6): 1202-1209.
19. Verstovsek S, Mesa RA, Gotlib J et al (2012b) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9): 799-807.
20. Verstovsek S, Mesa RA, Gotlib J, et al (2012c) Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Blood 120 (abstract 800) (ASH Annual Meeting Abstracts).
21. Verstovsek S, Mesa RA, Gotlib J et al (2013) The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 161(4): 508-516.